thymalfasin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Such use is prohibited by the rules of the governing bodies of most sports. AAS use occurs among adolescents, especially by those participating in competitive sports. It has been suggested that the prevalence of use among high-school students in the U.S. may be as high as 2.7%.
Robert Graham Cooks is the Henry Bohn Hass Distinguished Professor of Chemistry in the Aston Laboratories for Mass Spectrometry at Purdue University. He is an ISI Highly Cited Chemist, with over 1,000 publications and an H-index of 150.
On January 18, 2015, Alice in Chains performed in the halftime show of the NFC Championship Game between the Seattle Seahawks and the Green Bay Packers at CenturyLink Field in Seattle. Cantrell is a lifelong Seahawks fan and often attends their games. In August 2015, Bassist Mike Inez said that the band had been "throwing around riffs for a new record" and "taking it nice and slow". The band toured in the summer of 2015 and the summer of 2016, including select shows opening for Guns N' Roses as part of the Not in This Lifetime... Tour. The band finished their 2016 tour with a concert at the Grand Sierra Resort and Casino in Reno, Nevada on October 8, 2016. In November 2016, Alice in Chains released a cover of the Rush song "Tears", which was included in the 40th anniversary release of the album 2112. The home video Live Facelift was released on vinyl for the first time on November 25, 2016, as part of Record Store Day's Black Friday event. The album features six songs and only 5000 copies were issued. To celebrate the tenth anniversary of Record Store Day, on April 22, 2017, Legacy Recordings released "Get Born Again"/"What the Hell Have I", a special 45 RPM double 7" single featuring four tracks remastered and available on vinyl for the first time, "What the Hell Have I", "A Little Bitter", "Get Born Again" and "Died".
For some substances, such as carbon and arsenic, sublimation from solid state is much more achievable than evaporation from liquid state and it is difficult to obtain them as liquids. This is because the pressure of their triple point in its phase diagram (which corresponds to the lowest pressure at which the substance can exist as a liquid) is very high. Sublimation is caused by the absorption of heat which provides enough energy for some molecules to overcome the attractive forces of their neighbors and escape into the vapor phase. Since the process requires additional energy, sublimation is an endothermic change. The enthalpy of sublimation (also called heat of sublimation) can be calculated by adding the enthalpy of fusion and the enthalpy of vaporization.
Sources: en.wikipedia.org
=== Outside Greece === Although frappés are commonly associated with Greece, their popularity has grown in other nations in the recent years. Frappés first became broadly known outside of Greece during the 2004 Summer Olympics in Athens, wherein many tourists became fond of them and an article was published in the Los Angeles Times. Immigrants and tourists in Greece have also helped to take the frappé abroad.
== Further reading == Polonsky, K. S. (2012). "The Past 200 Years in Diabetes". New England Journal of Medicine. 367 (14): 1332–1340. doi:10.1056/NEJMra1110560. PMID 23034021. American Association of Clinical Endocrinologists Type II Lifestyle Guidelines Archived 2019-01-27 at the Wayback Machine
== D == DAIDS – data safety and monitoring board (DSMB) – deletion – dementia – demyelination – dendrite – dendritic cells – deoxyribonucleic acid (DNA) – Department of Health and Human Services (DHHS/HHS or DHHS) – desensitization – diabetes mellitus (DM) – diagnosis – diarrhea – diplopia – dissemination – division of acquired immunodeficiency syndrome (DAIDS) – DNA – dose-ranging study – dose-response relationship – double-blind study – drug resistance – drug-drug interaction – DSMB – Duffy antigen system – dysplasia – dyspnea
The DSQ is a questionnaire designed to measure difficulty swallowing associated with eosinophilic esophagitis, with total scores ranging from 0 to 84; higher DSQ scores indicate worse symptoms. The efficacy and safety of dupilumab to treat prurigo nodularis among adults were evaluated in two clinical trials, EFC16459 (PRIME) and EFC16460 (PRIME2). Each trial evaluated 300 mg of dupilumab administered every 2 weeks following an initial dose of 600 mg. The treatment lasted for 24 weeks. Effectiveness was mainly assessed by the proportion of subjects whose itchy skin (pruritus) improved by more than four points on the Worst Itch Numeric Rating Scale, the proportion of subjects who achieved score of 0 or 1 on Investigator's Global Assessment PN-stage scale (the equivalent of 0-5 nodules), and the proportion of subjects who achieved a response on both scales at week 24. In June 2026, Alteogen disclosed that Sanofi had been utilizing its ALT-B4 recombinant human hyaluronidase platform since 2019 to develop a high-dose subcutaneous formulation of dupilumab.
=== Welsh === Llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogoch, a railway station on the island of Anglesey in Wales, is the longest place name in the Welsh language. At 51 letters in the Welsh alphabet (the digraphs ll and ch are each collated as single letters) the name can be translated as "St Mary's church in the hollow of the white hazel near to the rapid whirlpool and the church of St Tysilio of the red cave". However, it was artificially contrived in the 1860s as a publicity stunt, to give the station the longest name of any railway station in the United Kingdom. Long words are comparatively rare in Welsh. Candidates for long words other than proper nouns include the following (the digraph dd is also treated as a single letter, as is ng in many instances including in the last word below):
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.